Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary Endpoints Met, Protocol-Defined Immune Responses Generated In 74% Of Participants

Loading news article.

Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary Endpoints Met, Protocol-Defined Immune Responses Generated In 74% Of Participants | WAPE

Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary Endpoints Met, Protocol-Defined Immune Responses Generated In 74% Of Participants

Article summary

Related companies

Comments —